دورية أكاديمية
Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series
| العنوان: | Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series |
|---|---|
| المؤلفون: | Yamamoto, Noboru, Tolcher, Anthony, Hafez, Navid, Lugowska, Iwona, Ramlau, Rodryg, Macarulla, Teresa |
| المساهمون: | Institut Català de la Salut, Yamamoto N Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan. Tolcher A NEXT Oncology, San Antonio, TX, USA. Hafez N Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA. The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA. Lugowska I Early Phase Clinical Trials Unit, Maria Skłodowska Curie National Research Institute of Oncology, Warsaw, Poland. Ramlau R Institute of Oncology, Poznan University of Medical Sciences, Poznan, Poland. Macarulla T Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| المصدر: | Scientia |
| بيانات النشر: | Dove Medical Press |
| سنة النشر: | 2024 |
| مصطلحات موضوعية: | Avaluació de resultats (Assistència sanitària), Conductes biliars - Càncer - Tractament, Quimioteràpia combinada, Proteïnes supressores de tumors, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Biliary Tract Neoplasms::Bile Duct Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Carrier Proteins::Poly-ADP-Ribose Binding Proteins::Tumor Suppressor Protein p53, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias del tracto biliar::neoplasias de los conductos biliares, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas transportadoras::proteínas de unión a poli-ADP-ribosa::proteína supresora de tumor p53 |
| الوصف: | Biliary tract cancer; Brigimadlin; Ezabenlimab ; Càncer de les vies biliars; Brigimadlin; Ezabenlimab ; Cáncer de las vías biliares; Brigimadlina; Ezabenlimab ; Background: In patients with advanced biliary tract cancer (BTC), first-line chemotherapy plus immunotherapy has improved outcomes; however, second-line options that reflect the disease’s molecular heterogeneity are still needed. One emerging target is MDM2, amplified in ~5– 8% of BTC cases. Methods: This is a subset analysis of two ongoing Phase Ia/Ib trials assessing patients treated with brigimadlin (BI 907828; a highly potent, oral MDM2–p53 antagonist) ± ezabenlimab (PD-1 inhibitor) ± BI 754111 (anti-LAG-3; n = 1). Results: Results from 12 patients with BTC are shown (monotherapy: n = 6/combination: n = 6). Six patients achieved partial response (monotherapy: n = 2/combination: n = 4), four had stable disease; responses were durable. Brigimadlin had a manageable safety profile. Seven patients had dose reductions due to adverse events, but no treatment-related adverse events led to treatment discontinuation. Conclusion: Brigimadlin demonstrated anti-tumor activity in patients with advanced MDM2-amplified BTC, and warrants further investigation. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1178-6930 |
| العلاقة: | OncoTargets and Therapy;17; https://doi.org/10.2147/OTT.S440979Test; Yamamoto N, Tolcher A, Hafez N, Lugowska I, Ramlau R, Macarulla T, et al. Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series. Onco Targets Ther. 2024 Mar 29;17:267–80.; https://hdl.handle.net/11351/11357Test; 001194678500001 |
| DOI: | 10.2147/OTT.S440979 |
| الإتاحة: | https://doi.org/10.2147/OTT.S440979Test https://hdl.handle.net/11351/11357Test |
| حقوق: | Attribution-NonCommercial 4.0 International ; http://creativecommons.org/licenses/by-nc/4.0Test/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.D4396F83 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 11786930 |
|---|---|
| DOI: | 10.2147/OTT.S440979 |